Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT3219 in Advanced Solid Tumors
NCT07893054Phase 1Not yet recruiting
- Sponsor
- BioNTech SE
- Start
- Nov 2026
- Primary completion
- Jul 2029
01
Overview
Phase 1, open-label trial of BNT3219 in solid tumor (2 arms), sponsored by BioNTech SE. Primary endpoints: Dose-Limiting Toxicities up to 21 days, Treatment-Emergent Adverse Events and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
BNT3219
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07893054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07893054.